Free tool
FAERS Monitor: Gadavist
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 201277 or its brand name (Gadavist, Gadobutrol). Reports on generic versions are filed under their own applications.
Reports
4,907
Serious
2,187
45% of reports
Hospitalization
734
Death reported
189
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- urticaria1,188
- nausea890
- vomiting742
- pruritus730
- dyspnoea455
- erythema375
- dizziness244
- rash244
- cough231
- headache222
- throat irritation184
- contrast media reaction168
- feeling hot142
- sneezing141
- anaphylactic reaction139
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2009 | 1 |
| 2011 | 103 |
| 2012 | 442 |
| 2013 | 327 |
| 2014 | 364 |
| 2015 | 317 |
| 2016 | 373 |
| 2017 | 414 |
| 2018 | 310 |
| 2019 | 266 |
| 2020 | 177 |
| 2021 | 325 |
| 2022 | 307 |
| 2023 | 330 |
| 2024 | 353 |
| 2025 | 301 |
| 2026 | 197 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,252 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contrast media reactionSignal | 168 | 328.5 | 281.5 | 50,648 |
| urticariaSignal | 1,188 | 30.6 | 29.1 | 34,023 |
| sneezingSignal | 141 | 27.1 | 23.0 | 3,501 |
| throat irritationSignal | 184 | 17.6 | 15.3 | 2,867 |
| anaphylactic reactionSignal | 139 | 10.8 | 9.2 | 1,227 |
| feeling hotSignal | 142 | 9.9 | 8.5 | 1,135 |
| pruritusSignal | 730 | 8.2 | 7.6 | 4,652 |
| erythemaSignal | 375 | 7.8 | 7.1 | 2,246 |
| vomitingSignal | 742 | 6.8 | 6.3 | 3,723 |
| nauseaSignal | 890 | 4.8 | 4.5 | 2,796 |
| coughSignal | 231 | 3.5 | 3.1 | 422 |
| dyspnoeaSignal | 455 | 3.4 | 3.2 | 809 |
| rashSignal | 244 | 2.4 | 2.1 | 202 |
| dizzinessSignal | 244 | 2.1 | 1.9 | 142 |
| headache | 222 | 1.5 | 1.3 | 40 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.